本文選題：膀胱癌術(shù)后　切入點(diǎn)：表柔比星　出處：《青海大學(xué)》2017年碩士論文

【摘要】：目的:探究?jī)煞N作用機(jī)制不同的藥物表柔比星(epirubicin,EPI)和甘露聚糖肽(mannatide)聯(lián)合灌注治療膀胱癌術(shù)后的療效。方法:收集病例共92例,按照就診的順序隨機(jī)分組:A組(29例)用表柔比星40mg溶解于0.9%氯化鈉注射液30ml;B組(32例)用40mg甘露聚糖肽溶解于0.9%氯化鈉注射液30ml;C組(31例)用40mg表柔比星+40mg甘露聚糖肽溶解于0.9%氯化鈉注射液30ml。手術(shù)方式均為經(jīng)尿道膀胱腫瘤電切術(shù)(transurethral resection of bladder tumor,TURBT),術(shù)后1周開(kāi)始規(guī)律灌注,灌注治療均為一人操作,并嚴(yán)格按照無(wú)菌原則實(shí)施,通過(guò)隨訪比較三組患者術(shù)后的復(fù)發(fā)及不良反應(yīng)發(fā)生情況。結(jié)果:對(duì)三組患者隨訪1年,A組、B組和C組患者1年內(nèi)的膀胱癌復(fù)發(fā)率分別為31.03%(9/29)、34.38%(11/32)、3.22%(1/31),經(jīng)統(tǒng)計(jì)學(xué)分析,A組和B組差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.0125),而C組分別與A、B組比較,差異均有統(tǒng)計(jì)學(xué)意義(P0.0125)。A、B、C三組患者不良反應(yīng):膀胱刺激征發(fā)生率分別為48.28%、3.13%、16.13%,經(jīng)統(tǒng)計(jì)學(xué)分析,A組與B、C兩組的差異均有統(tǒng)計(jì)學(xué)意義(P0.0125),B、C兩組差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.0125);肉眼血尿發(fā)生率分別為17.24%、0%、6.45%,三組患者兩兩比較,差異均有統(tǒng)計(jì)學(xué)意義。結(jié)論:EPI和甘露聚糖肽聯(lián)合使用對(duì)于預(yù)防膀胱癌術(shù)后復(fù)發(fā)的療效優(yōu)于單一使用EPI或甘露聚糖肽,且毒副作用小,安全性高,值得臨床推廣;單獨(dú)使用EPI和甘露聚糖肽的抗腫瘤效果無(wú)明顯差異,但EPI的不良反應(yīng)明顯高于甘露聚糖肽;因研究時(shí)間有限,遠(yuǎn)期效果需更高層次的探究。
[Abstract]:Aim: to explore the efficacy of epirubicinine epirubicin (EPI) and mannose polypeptide (MGP) in the treatment of bladder cancer after operation.Methods: 92 cases were collected.Thirty two patients in group B were dissolved with epirubicin 40mg in 0.9% sodium chloride injection. 32 patients in group B were treated with 40mg mannose polypeptide dissolved in 0.9% sodium chloride injection. 31 patients in group C were treated with 40mg epirubicin 40mg.Glycopeptide was dissolved in 0.9% sodium chloride injection 30 ml.Transurethral resection of bladder tumor TURBT were all performed by transurethral resection of bladder tumor. Regular perfusion was performed 1 week after operation. The perfusion therapy was performed by one person and was performed strictly according to the principle of sterility.The recurrence and adverse reactions of the three groups were compared by follow-up.The incidence of bladder irritation was 48.28 and 3.13 respectively. The difference between group A and group B was statistically significant (P 0.0125). There was no significant difference between group A and group B (P 0.0125), and there was no significant difference between group C and group B (P 0.0125); the incidence of bladder irritation was 48.28% and 3.13%, respectively. There was no significant difference between group A and group B (P 0.0125), and there was no significant difference between group A and group B (P 0.0125), and there was no significant difference between group A and group B (P 0.0125).The birth rates were 17.24% and 6.45%, respectively.The difference was statistically significant.Conclusion the combined use of 1: EPI and mannopolyglycopeptide is more effective than EPI or mannopolyglycopeptide in preventing recurrence of bladder cancer after operation, and its toxicity is small and safety is high, so it is worth popularizing in clinic.There was no significant difference in antitumor effect between EPI and mannopoly-glycopeptide alone, but the adverse reaction of EPI was significantly higher than that of mannopoly-glycopeptide. Because of the limited research time, the long-term effect needed to be explored at a higher level.
【學(xué)位授予單位】：青海大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類(lèi)號(hào)】：R737.14

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 田永莉;王福紅;劉海;景翠萍;劉國(guó)芳;陳緒霞;;甘露聚糖肽致過(guò)敏性支氣管哮喘1例[J];醫(yī)學(xué)信息;2006年02期

2 王紅雁;;甘露聚糖肽的臨床應(yīng)用[J];現(xiàn)代醫(yī)藥衛(wèi)生;2010年21期

3 張紅巖;孫亞琴;;甘露聚糖肽輔助治療小兒反復(fù)呼吸道感染療效觀察[J];河北醫(yī)藥;2010年23期

4 賈玉玲;秦曉玲;郁志龍;;甘露聚糖肽對(duì)癌癥放療病人的作用[J];內(nèi)蒙古醫(yī)學(xué)院學(xué)報(bào);2012年S6期

5 石芳;;甘露聚糖肽致過(guò)敏性休克1例搶救體會(huì)[J];齊魯護(hù)理雜志;2006年01期

6 韓在剛;;甘露聚糖肽致不良反應(yīng)26例文獻(xiàn)分析[J];中國(guó)民康醫(yī)學(xué);2008年20期

7 張朕華;吉蕊;郭月芳;盛雨辰;霍志軍;梅其炳;;甘露聚糖肽對(duì)淋巴造血系統(tǒng)腫瘤支持治療的臨床薈萃研究[J];中國(guó)新藥雜志;2011年24期

8 尚東;神舟三號(hào)甘露聚糖肽口服液還您精氣神[J];醫(yī)藥與保健;2003年08期

9 張虹;;甘露聚糖肽配合化療治療中晚期非小細(xì)胞肺癌的臨床觀察[J];腫瘤基礎(chǔ)與臨床;2008年01期

10 王乾蕾;李運(yùn)景;;甘露聚糖肽致不良反應(yīng)分析[J];中國(guó)現(xiàn)代藥物應(yīng)用;2008年05期

相關(guān)會(huì)議論文 前2條

1 趙立新;王蔭琪;許俊;彭紅英;;甘露聚糖肽對(duì)成人原發(fā)性腎病綜合征的預(yù)防感染作用[A];中西醫(yī)結(jié)合學(xué)會(huì)腎病專(zhuān)業(yè)委員會(huì)2013年學(xué)術(shù)年會(huì)暨繼續(xù)教育學(xué)習(xí)班資料匯編[C];2013年

2 于oP;;甘露聚糖肽佐治小兒反復(fù)呼吸道感染療效及對(duì)患兒免疫功能影響臨床觀察[A];第二十七屆航天醫(yī)學(xué)年會(huì)暨第十屆航天護(hù)理年會(huì)論文匯編[C];2011年

相關(guān)碩士學(xué)位論文 前9條

1 呂婧;魔芋甘露聚糖肽的制備工藝及理化特性研究[D];陜西科技大學(xué);2015年

2 賈瑩;魔芋甘露聚糖肽的分離純化及抗腫瘤活性研究[D];陜西科技大學(xué);2016年

3 朱付勇;表柔比星與甘露聚糖肽聯(lián)合灌注治療膀胱癌術(shù)后的療效分析[D];青海大學(xué);2017年

4 李志虎;甘露聚糖肽對(duì)細(xì)胞因子誘導(dǎo)的殺傷細(xì)胞的活性的影響[D];蘭州大學(xué);2013年

5 邵靜可;魔芋甘露聚糖肽制備技術(shù)研究[D];陜西科技大學(xué);2014年

6 趙榮榮;甘露聚糖肽聯(lián)合5-氟尿嘧啶對(duì)肝癌HepG2細(xì)胞增殖及凋亡的影響[D];蘭州大學(xué);2010年

7 毛瑞娟;甘露聚糖肽制劑氨基酸指紋圖譜研究[D];陜西科技大學(xué);2014年

8 張彥梅;鏈球菌制劑甘露聚糖肽聯(lián)合放射治療對(duì)肺腺癌A549細(xì)胞作用的實(shí)驗(yàn)研究[D];鄭州大學(xué);2012年

9 李靜靜;甘露聚糖肽口服液中氨基酸的測(cè)定以及指紋圖譜研究[D];西安理工大學(xué);2010年

，

本文編號(hào)：1725137